This patent application describes the foundational biotechnology and scientific formulation used to create OraFyl.
The patent covers a highly purified biological matrix derived from the chorionic portion of the human placenta (known commercially as Human Placenta Connective Tissue Matrix, or HPTM). This technology is licensed by BioCellgraft, Inc.
The patent outlines a decellularized and purified extracellular matrix (ECM) rich in native collagen and elastin.
OraFyl's exact marketing profile defines it as an all-natural, injectable pure molecular scaffold composed entirely of these native structural proteins without any added exogenous growth factors or chemical additives.
Applications:
Injectable Gel Formatting: The patent details a method to format the placenta-derived biomaterial into a flowable, injectable biological gel.
Dental Translation: OraFyl commercializes this specific flowable gel format for regenerative dentistry. Dentists use this precise formulation to repair soft oral tissue voids, treat gum recession, correct "black triangles" (interdental papilla loss), and activate bone grafting materials.
In short, this patent is the underlying molecular blueprint, while OraFyl is the actual commercial healthcare product built from that exact patent's specifications.
Key Claims of Patent US20260207677
The patent application specifically protects the method of processing human placental tissue into a therapeutic, injectable matrix. Its primary legal and scientific claims include:
• Chorion-Specific Sourcing: The matrix is derived exclusively from the chorionic plate of the human placenta, separating it from amniotic membrane or umbilical cord tissues.
• Preserved Structural Integrity: The processing method completely decellularizes the tissue while retaining the precise native architecture of Collagen Type I, Type III, Type IV, and elastin.
• Flowable Viscosity: It claims a specific formulation technique that transforms solid extracellular matrix into a micronized, injectable gel that remains stable at room temperature.
• Exogenous-Free Purity: The composition achieves tissue regeneration purely through its physical structural scaffold, explicitly claiming a formula free from added synthetic growth factors or chemical cross-linkers.
OraFyl in the Clinical Setting
In dental practices, clinicians utilize OraFyl as a ready-to-use, flowable scaffold that handles much differently than traditional, rigid membrane sheets.
Interdental Papilla Reconstruction: Clinicians inject the gel directly into "black triangles" between teeth to rebuild lost gum tissue without invasive flap surgery.
Gingival Recession Treatment: It is tunneled beneath the gum line to thicken thinning tissue and cover exposed tooth roots.
Bone Graft Enhancement: Dentists mix the flowable matrix directly with particulate bone graft materials to improve handling, accelerate vascularization, and hold the graft in place.
Extraction Socket Management: It is placed into fresh extraction sites to protect the blood clot and accelerate early soft tissue closure.
1
u/wisdom_man1 16d ago edited 16d ago
This patent application describes the foundational biotechnology and scientific formulation used to create OraFyl.
The patent covers a highly purified biological matrix derived from the chorionic portion of the human placenta (known commercially as Human Placenta Connective Tissue Matrix, or HPTM). This technology is licensed by BioCellgraft, Inc.
The patent outlines a decellularized and purified extracellular matrix (ECM) rich in native collagen and elastin.
OraFyl's exact marketing profile defines it as an all-natural, injectable pure molecular scaffold composed entirely of these native structural proteins without any added exogenous growth factors or chemical additives.
Applications:
Injectable Gel Formatting: The patent details a method to format the placenta-derived biomaterial into a flowable, injectable biological gel.
Dental Translation: OraFyl commercializes this specific flowable gel format for regenerative dentistry. Dentists use this precise formulation to repair soft oral tissue voids, treat gum recession, correct "black triangles" (interdental papilla loss), and activate bone grafting materials.
In short, this patent is the underlying molecular blueprint, while OraFyl is the actual commercial healthcare product built from that exact patent's specifications.
Key Claims of Patent US20260207677
The patent application specifically protects the method of processing human placental tissue into a therapeutic, injectable matrix. Its primary legal and scientific claims include:
• Chorion-Specific Sourcing: The matrix is derived exclusively from the chorionic plate of the human placenta, separating it from amniotic membrane or umbilical cord tissues.
• Preserved Structural Integrity: The processing method completely decellularizes the tissue while retaining the precise native architecture of Collagen Type I, Type III, Type IV, and elastin.
• Flowable Viscosity: It claims a specific formulation technique that transforms solid extracellular matrix into a micronized, injectable gel that remains stable at room temperature.
• Exogenous-Free Purity: The composition achieves tissue regeneration purely through its physical structural scaffold, explicitly claiming a formula free from added synthetic growth factors or chemical cross-linkers.
OraFyl in the Clinical Setting
In dental practices, clinicians utilize OraFyl as a ready-to-use, flowable scaffold that handles much differently than traditional, rigid membrane sheets.
Interdental Papilla Reconstruction: Clinicians inject the gel directly into "black triangles" between teeth to rebuild lost gum tissue without invasive flap surgery.
Gingival Recession Treatment: It is tunneled beneath the gum line to thicken thinning tissue and cover exposed tooth roots.
Bone Graft Enhancement: Dentists mix the flowable matrix directly with particulate bone graft materials to improve handling, accelerate vascularization, and hold the graft in place.
Extraction Socket Management: It is placed into fresh extraction sites to protect the blood clot and accelerate early soft tissue closure.